157 related articles for article (PubMed ID: 20029953)
1. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
[TBL] [Abstract][Full Text] [Related]
2. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
[TBL] [Abstract][Full Text] [Related]
3. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
Tefferi A; Mesa RA; Pardanani A; Hussein K; Schwager S; Hanson CA; Steensma DP
Am J Hematol; 2009 May; 84(5):265-7. PubMed ID: 19396855
[TBL] [Abstract][Full Text] [Related]
4. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
[TBL] [Abstract][Full Text] [Related]
5. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.
Patnaik MM; Caramazza D; Gangat N; Hanson CA; Pardanani A; Tefferi A
Eur J Haematol; 2010 Feb; 84(2):105-8. PubMed ID: 19895568
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.
Bacigalupo A; Soraru M; Dominietto A; Pozzi S; Geroldi S; Van Lint MT; Ibatici A; Raiola AM; Frassoni F; De Stefano F; Verdiani S; Casarino L; Barosi G
Bone Marrow Transplant; 2010 Mar; 45(3):458-63. PubMed ID: 19718055
[TBL] [Abstract][Full Text] [Related]
7. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
8. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
9. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
10. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A
Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987
[TBL] [Abstract][Full Text] [Related]
11. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
12. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
13. Stem cell transplantation for myelofibrosis: a report from two Canadian centers.
Daly A; Song K; Nevill T; Nantel S; Toze C; Hogge D; Forrest D; Lavoie J; Sutherland H; Shepherd J; Hasegawa W; Lipton J; Messner H; Kiss T
Bone Marrow Transplant; 2003 Jul; 32(1):35-40. PubMed ID: 12815476
[TBL] [Abstract][Full Text] [Related]
14. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
15. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
16. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
Gangat N; Caramazza D; Vaidya R; George G; Begna K; Schwager S; Van Dyke D; Hanson C; Wu W; Pardanani A; Cervantes F; Passamonti F; Tefferi A
J Clin Oncol; 2011 Feb; 29(4):392-7. PubMed ID: 21149668
[TBL] [Abstract][Full Text] [Related]
17. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.
Elena C; Passamonti F; Rumi E; Malcovati L; Arcaini L; Boveri E; Merli M; Pietra D; Pascutto C; Lazzarino M
Haematologica; 2011 Jan; 96(1):167-70. PubMed ID: 20884708
[TBL] [Abstract][Full Text] [Related]
18. [Clinical features and prognostic factors in primary myelofibrosis patients under 45 years old].
Lu L; Xiao ZJ; Chen HS; Lin H; Han ZC
Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):281-4. PubMed ID: 15949290
[TBL] [Abstract][Full Text] [Related]
19. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
[TBL] [Abstract][Full Text] [Related]
20. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.
Cermák J; Vítek A; Michalová K
Leuk Res; 2004 Jun; 28(6):551-7. PubMed ID: 15120930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
